ZA9811178B - Use of pyrazolo (3,4-b) pyridine as cyclin dependent kinase inhibitors. - Google Patents
Use of pyrazolo (3,4-b) pyridine as cyclin dependent kinase inhibitors.Info
- Publication number
- ZA9811178B ZA9811178B ZA9811178A ZA9811178A ZA9811178B ZA 9811178 B ZA9811178 B ZA 9811178B ZA 9811178 A ZA9811178 A ZA 9811178A ZA 9811178 A ZA9811178 A ZA 9811178A ZA 9811178 B ZA9811178 B ZA 9811178B
- Authority
- ZA
- South Africa
- Prior art keywords
- pyrazolo
- pyridine
- kinase inhibitors
- dependent kinase
- cyclin dependent
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Transplantation (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Molecular Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US6963397P | 1997-12-13 | 1997-12-13 |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA9811178B true ZA9811178B (en) | 2000-06-07 |
Family
ID=22090219
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA9811178A ZA9811178B (en) | 1997-12-13 | 1998-12-07 | Use of pyrazolo (3,4-b) pyridine as cyclin dependent kinase inhibitors. |
Country Status (11)
Country | Link |
---|---|
US (1) | US6107305A (ja) |
EP (1) | EP1043998B1 (ja) |
JP (1) | JP2002508324A (ja) |
AR (1) | AR017852A1 (ja) |
AT (1) | ATE355841T1 (ja) |
AU (1) | AU747705C (ja) |
CA (1) | CA2314355A1 (ja) |
DE (1) | DE69837282T2 (ja) |
ES (1) | ES2281941T3 (ja) |
WO (1) | WO1999030710A1 (ja) |
ZA (1) | ZA9811178B (ja) |
Families Citing this family (65)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1003519A4 (en) * | 1997-03-03 | 2003-08-20 | Univ Texas | SUPPRESSION OF CYCLINKINASE-2 ACTIVITY FOR PREVENTION AND THERAPY OF DNA VIRAL INFECTIONS |
US6407103B2 (en) | 1998-04-21 | 2002-06-18 | Bristol-Myers Squibb Pharma Company | Indeno [1,2-c] pyrazol-4-ones and their uses |
US6326379B1 (en) * | 1998-09-16 | 2001-12-04 | Bristol-Myers Squibb Co. | Fused pyridine inhibitors of cGMP phosphodiesterase |
US20040048844A1 (en) * | 1999-10-20 | 2004-03-11 | Bristol-Myers Squibb Pharma Company | Acylsemicarbazides as cyclin dependent kinase inhibitors useful as anti-cancer and anti-proliferative agents |
US6291504B1 (en) | 1999-10-20 | 2001-09-18 | Dupont Pharmaceuticals Company | Acylsemicarbazides and their uses |
FR2806626B1 (fr) * | 2000-03-22 | 2003-11-28 | Centre Nat Rech Scient | Utilisation de substances modulatrices de l'expression ou de la fonction d'une proteine impliquee dans le cycle cellulaire pour le traitement ou la prevention des lesions neurales aigues |
ES2236217T3 (es) * | 2000-04-25 | 2005-07-16 | Bristol-Myers Squibb Company | Uso de 5.tio.,sulfinil- y sulfonilpirazolo 3,4-b)-piridinas como inhibidores de la quinasa dependiente de la ciclina. |
WO2001082967A1 (en) * | 2000-04-28 | 2001-11-08 | Yamanouchi Pharmaceutical Co., Ltd. | MEDICINAL COMPOSITIONS FOR SUPPRESSING β-AMYLOID PRODUCTION |
KR100423899B1 (ko) * | 2000-05-10 | 2004-03-24 | 주식회사 엘지생명과학 | 세포 증식 억제제로 유용한 1,1-디옥소이소티아졸리딘을갖는 인다졸 |
PE20020394A1 (es) | 2000-08-18 | 2002-06-21 | Agouron Pharma | Compuestos de pirazol y composiciones farmaceuticas que los contienen, que modulan y/o inhiben la actividad de erab/hadh2 |
BR0113258A (pt) | 2000-08-18 | 2003-07-15 | Agouron Pharma | Compostos, pró-drogas, metabólitos ou sais, métodos de tratamento de condição doentia em mamìferos, mediada pela atividade de proteìna cinase e métodos de modulação ou inibição da atividade de um receptor de proteìna cinase |
AU2002213132A1 (en) * | 2000-10-10 | 2002-04-22 | Board Of Regents, The University Of Texas System | Suppression of cyclin kinase activity for prevention and treatment of infections |
US6706718B2 (en) * | 2000-12-01 | 2004-03-16 | Bristol-Myers Squibb Company | 3-(2,4-dimethylthiazol-5-yl)indeno[1,2-c]pyrazol-4-one derivatives and their uses |
AU2002228849A1 (en) | 2000-12-08 | 2002-06-18 | Bristol-Myers Squibb Pharma Company | Semicarbazides and their uses as cyclin dependent kinase inhibitors |
US6977262B2 (en) * | 2001-02-02 | 2005-12-20 | Mitsubishi Pharma Corporation | Dihydropyrazolopyridine compounds and pharmaceutical use thereof |
CA2446939C (en) * | 2001-05-16 | 2005-08-02 | Matthias Stein-Gerlach | Pyridylpyrimidine derivatives as effective compounds against prion diseases |
JP3896309B2 (ja) | 2001-07-09 | 2007-03-22 | ファイザー株式会社 | プロテインキナーゼc阻害物質としてのピラゾロキノリノン誘導体 |
US7271261B2 (en) * | 2001-10-19 | 2007-09-18 | Ortho-Mcneil Pharmaceutical, Inc. | Substituted benzimidazoles and imidazo-[4,5]-pyridines |
US20050154046A1 (en) * | 2004-01-12 | 2005-07-14 | Longgui Wang | Methods of treating an inflammatory-related disease |
US20100098702A1 (en) | 2008-09-16 | 2010-04-22 | Longgui Wang | Method of treating androgen independent prostate cancer |
US7582670B2 (en) | 2001-12-13 | 2009-09-01 | Natrogen Therapeutics, Inc. | Methods of treating an inflammatory-related disease |
US8748475B2 (en) | 2004-01-12 | 2014-06-10 | Natrogen Therapeutics International, Inc. | Methods and compositions for treating lupus |
GB0218625D0 (en) * | 2002-08-10 | 2002-09-18 | Astex Technology Ltd | Pharmaceutical compounds |
US7119200B2 (en) * | 2002-09-04 | 2006-10-10 | Schering Corporation | Pyrazolopyrimidines as cyclin dependent kinase inhibitors |
TWI344468B (en) * | 2002-09-04 | 2011-07-01 | Schering Corp | Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors |
US8580782B2 (en) * | 2002-09-04 | 2013-11-12 | Merck Sharp & Dohme Corp. | Substituted pyrazolo[1,5-a]pyrimidines as cyclin dependent kinase inhibitors |
US7196078B2 (en) * | 2002-09-04 | 2007-03-27 | Schering Corpoartion | Trisubstituted and tetrasubstituted pyrazolopyrimidines as cyclin dependent kinase inhibitors |
US8673924B2 (en) * | 2002-09-04 | 2014-03-18 | Merck Sharp & Dohme Corp. | Substituted pyrazolo[1,5-a]pyrimidines as cyclin dependent kinase inhibitors |
CN100376580C (zh) * | 2002-09-04 | 2008-03-26 | 先灵公司 | 作为细胞周期蛋白依赖性激酶抑制剂的吡唑并嘧啶 |
US7161003B1 (en) * | 2002-09-04 | 2007-01-09 | Schering Corporation | Pyrazolopyrimidines as cyclin dependent kinase inhibitors |
AU2003263071B2 (en) * | 2002-09-04 | 2007-03-15 | Merck Sharp & Dohme Llc | Pyrazolopyrimidines as cyclin-dependent kinase inhibitors |
MXPA05003059A (es) * | 2002-09-19 | 2005-05-27 | Schering Corp | Pirazolopiridinas como inhibidores de cinasa dependientes de ciclina. |
UA81453C2 (en) * | 2003-02-27 | 2008-01-10 | Pyrazolopyridine derivates | |
ATE363905T1 (de) | 2003-04-17 | 2007-06-15 | Janssen Pharmaceutica Nv | 2-phenyl-benzimidazol und 2-phenyl-imidazo-4,5)- pyridin-derivate als checkpoint-kinase-cds1 (chk2)-hemmer zur behandlung von krebs |
AR045037A1 (es) * | 2003-07-10 | 2005-10-12 | Aventis Pharma Sa | Tetrahidro-1h-pirazolo [3,4-c] piridinas sustituidas, composiciones que las contienen y su utilizacion. |
FR2857363B1 (fr) * | 2003-07-10 | 2007-09-07 | Aventis Pharma Sa | 4,5,6,7-tetrahydro-1h-pyrazolo[3,4-c] pyridines substituees compositions les contenant et utilisation |
US7405220B2 (en) * | 2004-06-09 | 2008-07-29 | Hoffmann-La Roche Inc. | Pyrazolopyrimidines |
WO2006002119A2 (en) | 2004-06-18 | 2006-01-05 | Gpc Biotech, Inc. | Kinase inhibitors for treating cancers |
ATE432921T1 (de) | 2004-12-23 | 2009-06-15 | Gpc Biotech Ag | Quadratsäurederivate mit antiproliferativer wirkung |
DE602006005242D1 (de) | 2005-06-27 | 2009-04-02 | Sanofi Aventis | Pyrazolopyridinderivate als inhibitoren der kinase 1 des beta-adrenergen rezeptors |
DE602005018911D1 (de) * | 2005-07-20 | 2010-03-04 | Aventis Pharma Sa | 1,4-Dihydropyridine-kondensierte Heterocyclen Verfahren zu deren Herstellung sowie Verwendung und Zusammensetzungen dergleichen |
JP2009507843A (ja) * | 2005-09-09 | 2009-02-26 | シェーリング コーポレイション | アザ縮合サイクリン依存性キナーゼ阻害剤 |
KR20080063806A (ko) | 2005-10-06 | 2008-07-07 | 쉐링 코포레이션 | 단백질 키나제 억제제로서의 피라졸로피리미딘 |
AR056785A1 (es) * | 2005-11-10 | 2007-10-24 | Schering Corp | COMPUESTOS DE IMIDAZO[1,2-A]PIRAZINAS, uTILES COMO INHIBIDORES, REGULADORES O MODULADORES DE PROTEINQUINASAS |
US7705009B2 (en) * | 2005-11-22 | 2010-04-27 | Hoffman-La Roche Inc. | 4-aminopyrimidine-5-thione derivatives |
RU2008139599A (ru) | 2006-03-07 | 2010-04-20 | Эррэй Биофарма Инк. (Us) | Гетеробициклические производные пиразола и способы их применения |
US20090175852A1 (en) | 2006-06-06 | 2009-07-09 | Schering Corporation | Imidazopyrazines as protein kinase inhibitors |
EP1914234A1 (en) * | 2006-10-16 | 2008-04-23 | GPC Biotech Inc. | Pyrido[2,3-d]pyrimidines and their use as kinase inhibitors |
JP5063700B2 (ja) | 2006-10-31 | 2012-10-31 | シェーリング コーポレイション | アニリノピペラジン誘導体およびアニリノピペラジン誘導体を使用する方法 |
CN101568527A (zh) * | 2006-10-31 | 2009-10-28 | 先灵公司 | 作为蛋白激酶抑制剂的2-氨基噻唑-4-羧酰胺 |
US8227605B2 (en) * | 2006-10-31 | 2012-07-24 | Schering Corporation | 2-aminothiazole-4-carboxylic amides as protein kinase inhibitors |
US8450348B2 (en) * | 2007-02-21 | 2013-05-28 | Forma Tm, Llc | Derivatives of squaric acid with anti-proliferative activity |
WO2008140724A1 (en) | 2007-05-08 | 2008-11-20 | Schering Corporation | Methods of treatment using intravenous formulations comprising temozolomide |
BRPI0908268A2 (pt) | 2008-02-29 | 2018-10-30 | Array Biopharma Inc | compostos do inibidor de raf e seus métodos de uso |
EP2112150B1 (en) | 2008-04-22 | 2013-10-16 | Forma Therapeutics, Inc. | Improved raf inhibitors |
EP2112152A1 (en) | 2008-04-22 | 2009-10-28 | GPC Biotech AG | Dihydropteridinones as Plk Inhibitors |
WO2011000566A2 (en) * | 2009-06-30 | 2011-01-06 | Savira Pharmaceuticals Gmbh | Compounds and pharmaceutical compositions for the treatment of negative-sense ssrna virus infections |
WO2011025706A2 (en) | 2009-08-26 | 2011-03-03 | Schering Corporation | Heterocyclic amide compounds as protein kinase inhibitors |
EP2325185A1 (en) | 2009-10-28 | 2011-05-25 | GPC Biotech AG | Plk inhibitor |
HU0900798D0 (en) | 2009-12-21 | 2010-03-01 | Vichem Chemie Kutato Kft | 4-phenylamino-pyrimidine derivatives having protein kinase inhibitor activity |
RU2011122942A (ru) | 2011-06-08 | 2012-12-20 | Общество С Ограниченной Ответственностью "Асинэкс Медхим" | Новые ингибиторы киназ |
WO2013148775A1 (en) | 2012-03-30 | 2013-10-03 | Merck Sharp & Dohme Corp. | Predictive biomarker useful for cancer therapy mediated by a cdk inhibitor |
ES2703851T3 (es) | 2014-08-22 | 2019-03-12 | Merck Patent Gmbh | Indazoles |
EP3712127A1 (en) | 2019-03-22 | 2020-09-23 | Deutsches Krebsforschungszentrum | Novel inhibitors of histone deacetylase 10 |
JP2022524887A (ja) | 2019-03-22 | 2022-05-10 | ドイチェス クレブスフォルシュングスツェントルム | ヒストンデアセチラーゼ10の新規の阻害剤 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE1923990C3 (de) * | 1969-05-10 | 1978-11-23 | Bayer Ag | Verfahren zur Herstellung von N-substituierten M-Dihydropyridin-S.S-dicarbonsäureestern |
BE787249A (fr) * | 1971-08-05 | 1973-02-05 | Squibb & Sons Inc | Derives amino d'acides pyrazolopyridine carboxyliques, leurs esters et les sels de ces composes, ainsi que leurs procedes de preparation |
US3810905A (en) * | 1971-11-04 | 1974-05-14 | Squibb & Sons Inc | Pyrazolo(3,4-b)pyridine-5-carboxamides |
US3773778A (en) * | 1972-01-24 | 1973-11-20 | Squibb & Sons Inc | Sulfur derivatives of pyrazolo (3,4-b)pyridines |
US3987051A (en) * | 1975-04-16 | 1976-10-19 | E. R. Squibb & Sons, Inc. | Method for producing 1-unsubstituted pyrazolo[3,4-b]pyridine ketones |
US3985757A (en) * | 1975-09-17 | 1976-10-12 | E. R. Squibb & Sons, Inc. | Pyrazolopyridine ketones |
US4552883A (en) * | 1982-06-15 | 1985-11-12 | Ici Americas Inc. | Pyrazolo[3,4-b]pyridine carboxylic acid esters and their pharmaceutical use |
US5733920A (en) * | 1995-10-31 | 1998-03-31 | Mitotix, Inc. | Inhibitors of cyclin dependent kinases |
-
1998
- 1998-12-07 AU AU16297/99A patent/AU747705C/en not_active Ceased
- 1998-12-07 AT AT98960781T patent/ATE355841T1/de not_active IP Right Cessation
- 1998-12-07 WO PCT/US1998/025920 patent/WO1999030710A1/en active IP Right Grant
- 1998-12-07 EP EP98960781A patent/EP1043998B1/en not_active Expired - Lifetime
- 1998-12-07 ZA ZA9811178A patent/ZA9811178B/xx unknown
- 1998-12-07 JP JP2000538693A patent/JP2002508324A/ja not_active Withdrawn
- 1998-12-07 CA CA002314355A patent/CA2314355A1/en not_active Abandoned
- 1998-12-07 ES ES98960781T patent/ES2281941T3/es not_active Expired - Lifetime
- 1998-12-07 DE DE69837282T patent/DE69837282T2/de not_active Expired - Lifetime
- 1998-12-11 US US09/209,575 patent/US6107305A/en not_active Expired - Lifetime
- 1998-12-11 AR ARP980106323A patent/AR017852A1/es unknown
Also Published As
Publication number | Publication date |
---|---|
CA2314355A1 (en) | 1999-06-24 |
WO1999030710A1 (en) | 1999-06-24 |
US6107305A (en) | 2000-08-22 |
AU1629799A (en) | 1999-07-05 |
EP1043998A4 (en) | 2004-02-04 |
DE69837282D1 (de) | 2007-04-19 |
EP1043998B1 (en) | 2007-03-07 |
AU747705C (en) | 2004-09-23 |
ES2281941T3 (es) | 2007-10-01 |
DE69837282T2 (de) | 2007-11-08 |
AR017852A1 (es) | 2001-10-24 |
AU747705B2 (en) | 2002-05-23 |
JP2002508324A (ja) | 2002-03-19 |
ATE355841T1 (de) | 2007-03-15 |
EP1043998A1 (en) | 2000-10-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA9811178B (en) | Use of pyrazolo (3,4-b) pyridine as cyclin dependent kinase inhibitors. | |
AU2002222293A1 (en) | Pyrazolo(3,4-c)pyridines as gsk-3 inhibitors | |
SI1220856T1 (en) | Pyrazolo(4,3-d)pyrimidine derivatives | |
AU6230098A (en) | Isoquinolinone derivatives, process for preparing the same, and their use as phosphodiesterase inhibitors | |
IL149025A0 (en) | 5-(2-substituted-5-heterocyclylsulphonylpyrid-3-yl)-dihydropyrazolo [4, 3-d] pyrimidin-7-ones as phosphodiesterase inhibitors | |
HK1018439A1 (en) | 5h-thiazolo (3,2-a) pyrimidine derivatives | |
ZA9810332B (en) | Aminothiazone inhibitors of cyclin dependent kinases. | |
SI1235830T1 (en) | PYRROLO(2,3-d)PYRIMIDINE COMPOUNDS AS PROTEIN KINASES INHIBITORS | |
AU1595197A (en) | Novel pyrrolo{2,3-d}pyrimidines and their use as tyrosine kinase inhibitors | |
HUP0001054A3 (en) | 1-aryl-1,8-naphthyridin-4-one derivative as type iv phosphodiesterase inhibitor | |
AU4308397A (en) | Substituted 2-pyrimidineamines, their preparation and their use as proteine kinase inhibitors | |
MY121867A (en) | Novel triazolo(4,5-d)pyrimidine compounds. | |
SG71077A1 (en) | 8-Substituted-1,3, 8-triaza-spiro (4.5)decan-4-on derivatives | |
ZA985121B (en) | 3-Substituted 3,4-dihyrothieno(2,3-d)pyrimidine derivatives their preparation and use. | |
ZA9711317B (en) | Substituted purine derivatives, processes for their preparation, their use, and compositions comprising them. | |
HK1053839A1 (en) | Novel 7-azaindoles, use thereof as phosphodiesterase 4 inhibitors and method for producing the same. | |
AU2002221753A1 (en) | Novel 7-azaindoles, use thereof as phosphodiesterase 4 inhibitors and method for producing the same | |
ZA975380B (en) | Bicyclic 4-aralkylaminopyrimidine derivatives as tyrosine kinase inhibitors. | |
EP1383769A4 (en) | PYRAZOLO 3,4-D] PYRIMIDINE-4-ONES 6-SUBSTITUTES USEFUL AS INHIBITORS OF KINASE DEPENDENT CYCLINES | |
CY2380B1 (en) | Pde IV inhibiting 2-cyanoiminoimidazole derivatives. | |
HK1039124A1 (en) | Phthalzaine derivatives phosphodiesterase 4 inhibitors. | |
PL350920A1 (en) | Substituted 3-cyano-[1.7], [1.5], and [1.8]-naphthyridine inhibitors of tyrosine kinases | |
AU5652698A (en) | (2,3-dihydrobenzofuranyl)-thiazoles as phosphodiesterase inhibitors | |
AU5491699A (en) | Process for the preparation of pyrrolo(2,3-d)pyrimidines | |
AU2253297A (en) | Imidazo{1,2-a}pyridine c-nucleosides as antiviral agents |